UNSPSC 51332003: Paliperidone

This classification denotes an antipsychotic agent with the molecular formula C23H27FN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 838F01T721, chemically known as 4h-pyrido(2,1-a)pyrimidin-4-one, 6,7,8,9-tetrahydro-3-(2-(4-(6-fluro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-9-hydroxy-2-methyl- but generally known as paliperidone, which bears US NIH Compound Identifier 115237. European Medicines Agency schedules Paliperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23268.

UNSPSC 51332003 Paliperidone is a Commodity code for pharmaceutical products, but the single recent state and local opportunity on record shows a mismatch: Seminole County, Florida posted an IFB on June 30, 2026 for naloxone and drug deactivation systems, not paliperidone. The code's nominal scope—a specific antipsychotic medication—does not align with the naloxone procurement actually being solicited. State and local activity under this code shows little relevant recent volume.

The Seminole County opportunity (IFB 60459723LAS, response due July 26, 2023) calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement is a two-year initial term with a one-year renewal option, awarded on a fixed-fee basis. Vendors must submit bids electronically, include all shipping and delivery costs, maintain workers' compensation and commercial general liability insurance, and comply with E-Verify and drug-free workplace requirements. The contract includes a three-month probationary period and is potentially FEMA-funded, triggering additional federal environmental compliance obligations. Without additional posted opportunities under this code, business development professionals should treat this Commodity code as inactive or misclassified in current state and local procurement databases.